Department of Health Studies and Applied Educational Psychology, Teachers College, Columbia University, New York, New York, USA,
Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Public Health Genomics. 2024;27(1):57-67. doi: 10.1159/000536391. Epub 2024 Feb 23.
Although the prevalence of a pathogenic variant in the BRCA1 and BRCA2 genes is about 1:400 (0.25%) in the general population, the prevalence is as high as 1:40 (2.5%) among the Ashkenazi Jewish population. Despite cost-effective preventive measures for mutation carriers, Orthodox Jews constitute a cultural and religious group that requires different approaches to BRCA1 and BRCA2 genetic testing relative to other groups. This study analyzed a dialog of key stakeholders and community members to explore factors that influence decision-making about BRCA1 and BRCA2 genetic testing in the New York Orthodox Jewish community.
Qualitative research methods, based on Grounded Theory and Narrative Research, were utilized to analyze the narrative data collected from 49 key stakeholders and community members. A content analysis was conducted to identify themes; inter-rater reliability was 71%.
Facilitators of genetic testing were a desire for preventive interventions and education, while barriers to genetic testing included negative emotions, feared impact on family/romantic relationships, cost, and stigma. Views differed on the role of religious leaders and healthcare professionals in medical decision-making. Education, health, and community were discussed as influential factors, and concerns were expressed about disclosure, implementation, and information needs.
This study elicited the opinions of Orthodox Jewish women (decision-makers) and key stakeholders (influencers) who play critical roles in the medical decision-making process. The findings have broad implications for engaging community stakeholders within faith-based or culturally distinct groups to ensure better utilization of healthcare services for cancer screening and prevention designed to improve population health.
虽然 BRCA1 和 BRCA2 基因的致病性变异在普通人群中的患病率约为 1:400(0.25%),但在阿什肯纳兹犹太人群中的患病率高达 1:40(2.5%)。尽管突变携带者有经济有效的预防措施,但东正教犹太人是一个文化和宗教群体,与其他群体相比,他们对 BRCA1 和 BRCA2 基因检测的需求需要采取不同的方法。本研究分析了关键利益相关者和社区成员的对话,以探讨影响纽约东正教犹太社区中 BRCA1 和 BRCA2 基因检测决策的因素。
采用扎根理论和叙事研究的定性研究方法,对从 49 名关键利益相关者和社区成员那里收集的叙事数据进行分析。采用内容分析法识别主题;评价者间的可靠性为 71%。
基因检测的促进因素是对预防干预和教育的渴望,而基因检测的障碍包括负面情绪、对家庭/浪漫关系的恐惧影响、成本和耻辱感。宗教领袖和医疗保健专业人员在医疗决策中的作用存在不同意见。教育、健康和社区被认为是有影响力的因素,并对披露、实施和信息需求表示担忧。
本研究征求了东正教犹太妇女(决策者)和关键利益相关者(影响者)的意见,他们在医疗决策过程中发挥着关键作用。这些发现对在信仰或文化上有差异的群体中吸引社区利益相关者具有广泛的意义,以确保更好地利用旨在改善人口健康的癌症筛查和预防保健服务。